Royal Bank Of Canada Gain Therapeutics, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.24 - $3.99 $307,942 - $990,880	-248,341 Reduced 99.94%	159 $0
Q1 2024 Nov 05, 2024	BUY	$3.21 - $5.04 $797,174 - $1.25 Million	248,341 Added 156189.31%	248,500 $936,000
Q1 2024 May 15, 2024	BUY	$3.21 - $5.04 $154,888 - $243,190	48,252 Added 24.1%	248,500 $936,000
Q4 2023 Feb 14, 2024	SELL	$2.07 - $3.4 $20,186 - $33,156	-9,752 Reduced 4.64%	200,248 $654,000
Q3 2023 Nov 14, 2023	BUY	$3.19 - $4.68 $605,953 - $888,984	189,954 Added 947.59%	210,000 $688,000
Q2 2023 Aug 14, 2023	SELL	$4.36 - $5.5 $82,639 - $104,247	-18,954 Reduced 48.6%	20,046 $89,000
Q4 2022 Feb 14, 2023	SELL	$2.89 - $3.35 $248 - $288	-86 Reduced 0.22%	39,000 $122,000
Q3 2022 Nov 14, 2022	BUY	$3.17 - $4.21 $272 - $362	86 Added 0.22%	39,086 $127,000
Q2 2022 Aug 15, 2022	SELL	$2.56 - $4.56 $28,160 - $50,159	-11,000 Reduced 22.0%	39,000 $140,000
Q1 2022 May 16, 2022	BUY	$3.15 - $5.59 $124,236 - $220,469	39,440 Added 373.48%	50,000 $205,000
Q4 2021 Feb 14, 2022	BUY	$5.3 - $9.24 $55,968 - $97,574	10,560 New	10,560 $57,000

2.39M

10K

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $19M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.